Biomarker-matched drug combos shrink treatment-resistant melanoma in preclinical models

MedicalXpress | 七月 02, 2026

A new study led by researchers at The University of Texas MD Anderson Cancer Center has identified a way to tailor drug combinations based on specific tumor biology to improve outcomes for treatment-resistant advanced melanoma.